Q32 Bio Stock Gets Increased EPS Estimate from HC Wainwright

Q32 Bio Inc. (NASDAQ:QTTB) – Investment analysts at HC Wainwright increased their FY2028 earnings per share (EPS) estimates for shares of Q32 Bio in a note issued to investors on Wednesday, September 30th. HC Wainwright analyst J. Pantginis now expects that the company will earn ($1.52) per share for the year, up from their prior forecast of ($1.80). HC Wainwright has a “Buy” rating and a $36.00 price target on the stock. The consensus estimate for Q32 Bio’s current full-year earnings is ($1.54) per share. HC Wainwright also issued estimates for Q32 Bio’s FY2029 earnings at $1.21 EPS and FY2030 earnings at $2.89 EPS.

Q32 Bio (NASDAQ:QTTB) last posted its earnings results on Wednesday, August 5th. The company reported ($0.44) EPS for the quarter, beating the consensus estimate of ($0.46) by $0.02.

A number of other equities analysts have also issued reports on the stock. Cantor Fitzgerald reiterated an “overweight” rating on shares of Q32 Bio in a research report on Wednesday, September 16th. Oppenheimer restated an “outperform” rating on shares of Q32 Bio in a research report on Thursday. Mizuho raised shares of Q32 Bio to a “strong-buy” rating in a research note on Monday, September 7th. Jefferies Financial Group began coverage on shares of Q32 Bio in a report on Monday, September 28th. They issued a “buy” rating and a $29.00 price objective for the company. Finally, Morgan Stanley assumed coverage on shares of Q32 Bio in a research note on Monday, August 24th. They set an “overweight” rating and a $34.00 price objective on the stock. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $30.60.

Q32 Bio Stock Performance

NASDAQ:QTTB opened at $8.37 on Monday. The stock has a market cap of $249.17 million, a price-to-earnings ratio of 2.79 and a beta of 0.31. Q32 Bio has a 1 year low of $1.90 and a 1 year high of $23.57. The business has a fifty day moving average of $13.13 and a 200-day moving average of $10.81.

Insider Activity at Q32 Bio

In other Q32 Bio news, CEO Jodie Morrison sold 9,845 shares of the company’s stock in a transaction dated Tuesday, August 25th. The shares were sold at an average price of $16.56, for a total value of $163,033.20. Following the completion of the sale, the chief executive officer directly owned 343,259 shares of the company’s stock, valued at approximately $5,684,369.04. This represents a 2.79% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Shelia M. Violette sold 2,798 shares of the firm’s stock in a transaction dated Tuesday, August 25th. The shares were sold at an average price of $16.56, for a total transaction of $46,334.88. Following the transaction, the insider owned 127,771 shares of the company’s stock, valued at approximately $2,115,887.76. This trade represents a 2.14% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 16,615 shares of company stock valued at $275,144 over the last 90 days. 34.46% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Q32 Bio

Several hedge funds have recently made changes to their positions in the business. Squarepoint Ops LLC purchased a new position in Q32 Bio in the 2nd quarter worth about $303,000. Atlas Venture Life Science Advisors LLC lifted its stake in Q32 Bio by 29.9% during the second quarter. Atlas Venture Life Science Advisors LLC now owns 2,717,106 shares of the company’s stock valued at $34,616,000 after buying an additional 625,000 shares in the last quarter. Susquehanna International Group LLP purchased a new stake in Q32 Bio during the second quarter valued at about $297,000. Carlyle Group Inc. purchased a new stake in Q32 Bio during the second quarter valued at about $769,000. Finally, BlackRock Inc. acquired a new position in shares of Q32 Bio in the second quarter worth about $1,510,000. Institutional investors and hedge funds own 31.32% of the company’s stock.

About Q32 Bio

Q32 Bio is a clinical-stage biotechnology company focused on developing therapies designed to restore immune homeostasis and address diseases driven by immune dysregulation. The company’s approach targets pathways involved in the transforming growth factor beta superfamily, which plays a role in regulating inflammation, tissue repair and immune responses.

Q32 Bio’s lead product candidate is bempikibart, also known as ADX-914, a fully human monoclonal antibody designed to modulate immune activity through selective targeting of the activin receptor type IIA pathway.